Novartis’ Kymriah shows durable response in blood cancer

11th December 2017 Uncategorised 0

New analysis of trial data on Novartis’ CAR-T therapy Kymriah presented at the 59th American Society of Hematology (ASH) annual meeting show that the drug sustained complete responses at six months in adults with a difficult to treat form of blood cancer.

More: Novartis’ Kymriah shows durable response in blood cancer
Source: News